drugset / Trial / NCT00479778

Study Of Pharmacokinetic (PK) Profile of Bazedoxifene (BZA) in 2 BZA/Conjugated Estrogen Forms

NCT00479778

Phase 1 Completed 72 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to understand how bazedoxifene is absorbed in the body when it is given in combination with 2 different formulations of conjugated estrogens. It is an open label study with no placebo control or comparator drugs. Subjects will take one dose of the investigation formulation daily for 14 days.

Timeline

Start
2007-04
Primary completion
Completion
2007-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Bazedoxifene Other / unclassified
Subject conjugated estrogens Other / unclassified

Indications

No indication recorded.